DCP Capital

Simple Love is a natural yoghurt brand.

Adopt A Cow is a fast-growing, direct-to-consumer dairy company in China that integrates digital solutions into its core operations.

Datong Insurance is a professional third-party financial insurance service organization. Datong’s subsidiaries include Datong Insurance Sales Service Co., Ltd., Beijing Datong Insurance Brokers Co., Ltd., among which Datong Insurance Sales Service Co., Ltd. is approved by the China Insurance Regulatory Commission. The first national insurance professional sales and service organization approved to be established. At present, the Datong service network has covered more than 20 provinces and municipalities across the country.

Valgen focus on treatment technologies and systemic solutions for heart disease, especially for mitral and tricuspid valve lesions.

Adopt A Cow is a fast-growing, direct-to-consumer dairy company in China that integrates digital solutions into its core operations.

Simple Love is a natural yoghurt brand.

Xingsheng Youxuan is a community shopping platform that provides fresh products for consumers. It relies on community-based offline convenience stores to meet the daily needs of household consumers through a new online order and offline pick-up retail model. The platform provides fresh vegetables, fruits, meat and poultry, seafood, common staples, seasoning, and other general merchandise. The company was founded in 2018 and is based in Changsha City, China.

Fenbi Wang provides vocational education examination services.

Founded in 2012, Yuanfudao is the largest online live courseplatform servicing primary and secondary school students in China. With a paying userbase of over 1 million, Yuanfudao offers a comprehensive curriculum spanning fromprimary school English, Mathematical Olympiad to all-subject courses in secondaryschool. Its unique online feature and large pool of quality teachers enable students toaccess live online tutoring at home taught by national renowned teachers, benefitinghundreds of thousands of students across the country.

Broncus Technologies is a medical technology company focused on developing minimally-invasive medical devices for emphysema and other lung diseases. Broncus is investigating the Exhale emphysema product line to perform our patented treatment method called Airway Bypass. Airway Bypass could be the first minimally-invasive procedure for the treatment of homogeneous, or diffuse, emphysema, which constitutes the majority of the emphysema patient population. Broncus is currently enrolling patients worldwide in our pivotal EASE Trial investigating a treatment of severe homogeneous emphysema. Broncus is located in Mountain View, CA (San Francisco Bay area). Broncus International is located in Nyon, Switzerland.

Tonghua Dongbao Pharma develops and markets recombinant human insulin for the treatment of diabetes.

Far East Horizon is a financial services organization. Far East Horizon is devoted to providing its customers with tailored industrial integrated operation services through continual innovation of products and services. Far East Horizon develops industry integrated operation services such as financial services, industrial investment and operation, operational leasing ,trade brokering, management consulting and construction services for multiple fields including health, packaging, transportation, construction, machinery, education, textiles, electronic information and public utilities. By matching up the organizational operation of financial resources with the discovery and cultivation of industrial resources, Far East Horizon creates an operational advantage with the characteristics of joint development of finance and industry.

Venus MedTech (HangZhou) Inc. is located in Hangzhou National High-tech Industrial Development Zone (Binjiang), with its products positioned in the development and industrialization of international advanced interventional artificial cardiac valve system, filling up the blank in China. Interventional artificial aortic valve products researched and developed by the company takes the lead in finishing clinical tests in China. In reference to the development and promotion conditions of coronary stents at home and abroad, interventional artificial cardiac valve, as a revolutionary treatment means, has been increasingly recognized by experts, and will take on an explosible increase of clinical needs in the foreseeable next few years.